VIVIMED LABS LTD.

Vivimed Labs Limited has issued a pre-facto intimation regarding the seventh meeting of its Committee of Creditors (CoC). The meeting is scheduled for Thursday, September 10, 2026, and will be conducted through Audio-Visual Means. This meeting is part of the company's ongoing corporate insolvency resolution process, initiated by an NCLT order dated April 15, 2026. The intimation is made in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and IBBI (Insolvency Resolution Process for Corporate Persons) Regulations, 2016.

Vivimed Labs Limited has issued a pre-facto intimation regarding the upcoming 6th Meeting of its Committee of Creditors (CoC). The meeting is scheduled to be held on August 18, 2026, via Audio-Visual Means, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and IBBI (Insolvency Resolution Process for Corporate Persons) Regulations, 2016. This intimation follows a series of previous CoC meetings, including the fifth meeting held on July 20, 2026. The company is undergoing a corporate insolvency resolution process.

Vivimed Labs Limited has re-lodged transfer requests for physical shares as per SEBI Circular No. SEBI/HO/38/13/11(2)2026-MIRSD-POD/1/3750/2026 dated January 30, 2026. The company, through its Registrar and Share Transfer Agent, Aarthi Consultants Pvt Ltd, has reported the status of these requests. As of June 2026, there were no requests received, processed, approved, or rejected during the relevant period. Consequently, the average processing time for requests was not applicable (NA). This information is for the information and records of the stock exchanges.

Vivimed Labs Ltd announced that its Board of Directors, operating under the Interim Resolution Professional (IRP) due to Corporate Insolvency Resolution Process (CIRP), has approved the audited financial results for the quarter and year ended March 31, 2026. The company reported a consolidated net loss of ₹1,716.11 Lakhs for the year ended March 31, 2026, a significant increase from the previous year's loss. Revenue from operations for the year stood at ₹103.60 Crores. The company continues to operate on a going concern basis, supported by management's belief in future operational improvements and promoter support, despite ongoing investigations and the CIRP proceedings initiated by a vendor.

Vivimed Labs Ltd has announced that its Board of Directors will convene on July 17, 2026, in Hyderabad. The primary agenda item for this meeting is to consider and approve the audited financial results, both standalone and consolidated, for the quarter and fiscal year ending March 31, 2026. The company has informed the BSE about this scheduled meeting in compliance with SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. Other business items may also be discussed.

Vivimed Labs Ltd has announced the closure of its trading window effective July 1, 2026. This closure is in accordance with the company's Code of Conduct for Prohibition of Insider Trading and will remain in effect until 48 hours after the declaration of the financial results for the quarter ended June 30, 2026. The specific date for the Board Meeting to approve these financial results will be communicated in due course. This measure is standard practice to prevent insider trading during the sensitive period leading up to financial result announcements.

Vivimed Labs Limited has issued a Form G inviting expressions of interest for its corporate insolvency resolution process. The company operates in the business of manufacturing pharma dosage forms across multiple locations in India, including Hyderabad, Haridwar, Kashipur, and Bidar. The filing provides details on installed capacities, revenue from operations for FY24-25 and FY23-24, and the number of employees. The last date for receipt of expressions of interest is June 29, 2026, with subsequent dates set for the provisional and final lists of prospective resolution applicants, and the submission of resolution plans.

The board meeting of Vivimed Labs Limited, previously scheduled for May 30, 2026, to approve the financial results for the quarter and year ended FY 2025-2026, has been postponed. The revised date will be communicated to the stock exchanges in due course. The trading window remains closed for designated persons until 48 hours after the financial results are declared following the rescheduled meeting.

Vivimed Labs Ltd has rescheduled its board meeting from May 28, 2026, to May 30, 2026, in Hyderabad. The meeting will consider and approve the audited financial results (standalone & consolidated) for the quarter and year ending March 31, 2026. The trading window remains closed for designated persons until 48 hours after the results are declared.

Vivimed Labs Ltd has scheduled a meeting of its Board of Directors on May 28, 2026, to consider and approve the audited financial results (standalone & consolidated) for the quarter and year ending March 31, 2026.